

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

23. (Twice amended) The method according to claims 21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is an allergic, inflammatory or autoimmune disease.

24. (Twice amended) The method according to claims 21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is bronchial asthma.

25. (Twice amended) The method according to claims 21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is rheumatoid arthritis.

Please add the following new claims:

30. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be substituted with one or more Alk.

31. The pharmaceutical composition which comprises a pyrazole derivative according to claim 10, wherein

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

506
C7
A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

32. The method for treating a disease associated with calcium release-activated
calcium channels according to claim 21, wherein

132
n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

33. The method for treating a disease associated with IL-2 production according to
claim 26, wherein

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

34. The method for treating an allergic, inflammatory or autoimmune disease
according to claim 27, wherein

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

Sub
C7
A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

35. The method for treating bronchial asthma according to claim 28, wherein

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

B2
A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

36. The method for treating rheumatoid arthritis according to claim 29, wherein

n is 0,

B is phenylene,

X is -NH-CO- or -CO-NH-, and

A is phenyl which may be substituted with one or more Hal; or monocyclic heteroaryl
selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be
substituted with one or more Alk.

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

37. The pyrazole derivative 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

38. The pharmaceutical composition which comprises a pyrazole derivative according to claim 10, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

39. The method for treating a disease associated with calcium release-activated calcium channels which comprises administering a pharmaceutical composition comprising a pyrazole derivative according to claim 21, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

40. The method for treating a disease associated with IL-2 production which comprises administering a pharmaceutical composition comprising a pyrazole derivative according to claim 26, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

41. The method for treating an allergic, inflammatory or autoimmune disease which comprises administering a pharmaceutical composition comprising a pyrazole derivative according to claim 27, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

42. The method for treating bronchial asthma which comprises administering a pharmaceutical composition comprising a pyrazole derivative according to claim 28, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT

Q62542

U.S. Appln. No. 09/773,736

Sub

c7

B2

43. The method for treating rheumatoid arthritis which comprises administering a pharmaceutical composition comprising a pyrazole derivative according to claim 29, wherein the pyrazole derivative is 4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.
